Allworth Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Allworth Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$255	Hold	26	–	–	﹤0.01%	4923
2026 Q1	$145	Hold	26	–	–	﹤0.01%	4964
2025 Q4	$192	Hold	26	–	–	﹤0.01%	4701
2025 Q3	$171	Sell	26 -6	-19%	-$32	﹤0.01%	4620
2025 Q2	$138	Hold	32	–	–	﹤0.01%	4365
2025 Q1	$192	Sell	32 -1	-3%	-$9	﹤0.01%	3878
2024 Q4	$334	Hold	33	–	–	﹤0.01%	3693
2024 Q3	$415	Hold	33	–	–	﹤0.01%	3461
2024 Q2	$445	Hold	33	–	–	﹤0.01%	3404
2024 Q1	$755	Hold	33	–	–	﹤0.01%	3164
2023 Q4	$433	Hold	33	–	–	﹤0.01%	3164
2023 Q3	$670	Hold	33	–	–	﹤0.01%	2971
2023 Q2	$895	Hold	33	–	–	﹤0.01%	2761
2023 Q1	$1.95K	Hold	33	–	–	﹤0.01%	2420
2022 Q4	$1.7K	Buy	33 +26	+371%	+$1.8K	﹤0.01%	2296
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	2419
2022 Q2	$0	Hold	7	–	–	﹤0.01%	2601
2022 Q1	$1K	Hold	7	–	–	﹤0.01%	1954
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	1833
2021 Q3	$1K	Hold	7	–	–	﹤0.01%	1771
2021 Q2	$1K	Sell	7 -22	-76%	-$3.19K	﹤0.01%	1467
2021 Q1	$5K	Buy	29 +22	+314%	+$4.63K	﹤0.01%	1137
2020 Q4	$2K	Buy	+7	New	+$1.62K	﹤0.01%	1170

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allworth Financial's KPTI Position: Q2 2026 in Review

Allworth Financial held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 26 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #4923.

Allworth Financial first reported a position in KPTI in Q4 2020 and has held it in 23 quarters since. The position peaked at $5K in Q1 2021. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Allworth Financial held 26 shares of Karyopharm Therapeutics worth $255 as of Q2 2026.
Allworth Financial left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4923 holding.
Allworth Financial first reported a position in Karyopharm Therapeutics in Q4 2020 and has held it in 23 quarters since.
Allworth Financial's Karyopharm Therapeutics position peaked at $5K in Q1 2021.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.